Elward David Crawford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elward David Crawford has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Kyle O. Rove
University of Colorado, Anschutz Medical Campus, Aurora, Colorado
3 shared publicationsCurtis A. Pettaway
Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publicationsGerald L. Andriole
Washington University School of Medicine St Louis MO USA
2 shared publicationsPaul Arangua
University of Colorado, Anschutz Medical Campus, Aurora, Colorado
2 shared publicationsAdrie Van Bokhoven
University of Colorado, Anschutz Medical Campus, Aurora, Colorado
1 shared publicationAlan W. Partin
Department of Pathology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 21 August 2018
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 22 (1) , 24-38
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
Background Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies that suppress testosterone (T) levels or inactivate its function, improvements in diagnostic and assay technologies, identification of lower therapeutic targets for T, discovery of the relevance of germline genetic mutations and identification of the benefits of sequential and combination therapies. Methods This review discusses the clinical profiles of the most up-to-date options for ADT, best practices for managing patients with advanced PCa and future directions in therapy. Results and conclusions Modern assay technologies reveal that bilateral orchiectomy results in a serum T level of approximately 15 ng/dL as compared to the historical definition of castration of T < 50 ng/dL. Evidence shows that lowering T levels to <20 ng/dL improves patient survival and delays disease progression. Routine monitoring of T in addition to prostate-specific antigen throughout treatment is important to ensure continuing efficacy of T suppression. New drugs that inhibit androgen signaling in combination with traditional ADT suppress T activity to near zero and have significantly improved patient survival. When personalizing ADT regimens physicians should consider a number of factors including initiation and duration of ADT, monitoring of T levels and PSA, the possibility of switching monotherapies if a patient does not achieve adequate T suppression, and consideration of intermittent vs. continuous ADT according to patients’ lifestyles, comorbidities, risk factors and tolerance to treatment.
- 21 August 2018
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 22 (1) , 24-38
Top Cited PapersOpen AccessAndrogen-targeted therapy in men with prostate cancer: evolving practice and future considerations
Background Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies that suppress testosterone (T) levels or inactivate its function, improvements in diagnostic and assay technologies, identification of lower therapeutic targets for T, discovery of the relevance of germline genetic mutations and identification of the benefits of sequential and combination therapies. Methods This review discusses the clinical profiles of the most up-to-date options for ADT, best practices for managing patients with advanced PCa and future directions in therapy. Results and conclusions Modern assay technologies reveal that bilateral orchiectomy results in a serum T level of approximately 15 ng/dL as compared to the historical definition of castration of T < 50 ng/dL. Evidence shows that lowering T levels to <20 ng/dL improves patient survival and delays disease progression. Routine monitoring of T in addition to prostate-specific antigen throughout treatment is important to ensure continuing efficacy of T suppression. New drugs that inhibit androgen signaling in combination with traditional ADT suppress T activity to near zero and have significantly improved patient survival. When personalizing ADT regimens physicians should consider a number of factors including initiation and duration of ADT, monitoring of T levels and PSA, the possibility of switching monotherapies if a patient does not achieve adequate T suppression, and consideration of intermittent vs. continuous ADT according to patients’ lifestyles, comorbidities, risk factors and tolerance to treatment.
- 19 February 2018
- Published by Wiley in The Prostate
- Vol. 78 (7) , 506-511
The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer
Background: The 4Kscore is a new commercially available blood‐based diagnostic test which predicts risk for aggressive, clinically significant prostate cancer on prostate biopsy. The 4Kscore is currently restricted to patients who have not had a digital rectal exam (DRE) in the previous 96 h, owing to prior mixed data suggesting that prostate specific antigen (PSA) isoforms may increase by a statistically significant—if not necessarily clinically significant—amount shortly after DRE. Our primary objective was to determine if 4Kscore test results are affected by a preceding DRE.Methods: Participants at a Prostate Cancer Awareness Week screening event sponsored by the Prostate Conditions Education Council filled out clinical history questionnaires and had blood samples for 4Kscore testing drawn prior to DRE, then 15‐45 min following DRE. Patients with prior cancer diagnosis, 5‐alpha reductase inhibitor medication use, or lower urinary tract procedures in the prior 6 months were excluded, resulting in a population of 162 participants for analysis. Values were then compared to determine if there was a significant difference in 4Kscore following DRE.Results: A statistically significant increase was seen in levels of 3 kallikreins measured (total PSA, free PSA, and intact PSA; median <0.03 ng/mL for all). This resulted in a small but statistically significant decrease in post‐DRE 4Kscore (median absolute score decrease 0.43%). Using a 4Kscore cutoff of 7.5% resulted in reclassification of 10 patients (6.2%), nine of whom were “downgraded” from above the cutoff to below.Conclusions: If the blood draw for the 4 K score is performed after a screening DRE, there is a statistically significant difference in the 4 K score results, but in the vast majority of cases it would not affect clinical decision making.
- 19 February 2018
- Published by Wiley in The Prostate
- Vol. 78 (7) , 506-511
The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer
Background: The 4Kscore is a new commercially available blood‐based diagnostic test which predicts risk for aggressive, clinically significant prostate cancer on prostate biopsy. The 4Kscore is currently restricted to patients who have not had a digital rectal exam (DRE) in the previous 96 h, owing to prior mixed data suggesting that prostate specific antigen (PSA) isoforms may increase by a statistically significant—if not necessarily clinically significant—amount shortly after DRE. Our primary objective was to determine if 4Kscore test results are affected by a preceding DRE.Methods: Participants at a Prostate Cancer Awareness Week screening event sponsored by the Prostate Conditions Education Council filled out clinical history questionnaires and had blood samples for 4Kscore testing drawn prior to DRE, then 15‐45 min following DRE. Patients with prior cancer diagnosis, 5‐alpha reductase inhibitor medication use, or lower urinary tract procedures in the prior 6 months were excluded, resulting in a population of 162 participants for analysis. Values were then compared to determine if there was a significant difference in 4Kscore following DRE.Results: A statistically significant increase was seen in levels of 3 kallikreins measured (total PSA, free PSA, and intact PSA; median <0.03 ng/mL for all). This resulted in a small but statistically significant decrease in post‐DRE 4Kscore (median absolute score decrease 0.43%). Using a 4Kscore cutoff of 7.5% resulted in reclassification of 10 patients (6.2%), nine of whom were “downgraded” from above the cutoff to below.Conclusions: If the blood draw for the 4 K score is performed after a screening DRE, there is a statistically significant difference in the 4 K score results, but in the vast majority of cases it would not affect clinical decision making.
- 4 July 2013
- Published by Wiley in BJU International
- Vol. 112 (5) , 548-560
The utility of prostate‐specific antigen in the management of advanced prostate cancer
To review current prostate‐specific antigen ( PSA ) metrics used in monitoring treatment of advanced prostate cancer, with a specific focus on castration‐resistant prostate cancer ( CRPC ) therapies. Explore what is known about the correlation between PSA and androgen levels as well as underlying reasons for persistent PSA expression and serum elevation in CRPC , and outline suggestions for use of PSA in managing patients with advanced prostate cancer. A comprehensive search of the PubMed database for E nglish language articles through A pril 2012 was performed using the following M edical S ubject H eadings ( MeSH ) keywords or terms, alone or in combination: ‘prostate cancer’; ‘prostate cancer treatment’; ‘prostate cancer outcomes’; ‘prostate‐specific antigen’; ‘androgen receptor’; ‘advanced prostate cancer’; ‘castration‐resistant prostate cancer’; ‘biomarkers’. Bibliographies of relevant articles were searched for additional references. Relevant medical society and regulatory agency web sites from the USA and E urope were accessed for issued guidance on PSA use. PSA doubling time ( PSADT ) is a useful metric for determining which patients should be considered for androgen‐deprivation therapy ( ADT ) after failing local treatment or for second‐line therapies after failing ADT . However, it is not a validated surrogate for survival and no therapy has received regulatory approval based upon PSADT characteristics. PSA nadir and time‐to‐nadir have been identified as possible prognostic markers for patients receiving ADT . There is no universally accepted definition for PSA progression, nor is PSA progression a regulatory‐approved surrogate for clinical progression in drug approval trials. PSA responses to second‐line therapies can vary and are not considered by regulatory agencies as valid surrogates for clinical endpoints, so they must be assessed in the context of each individual therapy and trial design. PSA expression in CRPC is often a reflection of persistent androgen receptor activity. While we can provide guidance for use of PSA monitoring in managing patients with advanced prostate cancer based on the data at hand, there is an urgent need for prospective analyses of refined PSA metrics in conjunction with newer prostate cancer biomarkers in clinical trials to provide stronger evidence for their roles as surrogate endpoints.
- 4 July 2013
- Published by Wiley in BJU International
- Vol. 112 (5) , 548-560
The utility of prostate‐specific antigen in the management of advanced prostate cancer
To review current prostate‐specific antigen ( PSA ) metrics used in monitoring treatment of advanced prostate cancer, with a specific focus on castration‐resistant prostate cancer ( CRPC ) therapies. Explore what is known about the correlation between PSA and androgen levels as well as underlying reasons for persistent PSA expression and serum elevation in CRPC , and outline suggestions for use of PSA in managing patients with advanced prostate cancer. A comprehensive search of the PubMed database for E nglish language articles through A pril 2012 was performed using the following M edical S ubject H eadings ( MeSH ) keywords or terms, alone or in combination: ‘prostate cancer’; ‘prostate cancer treatment’; ‘prostate cancer outcomes’; ‘prostate‐specific antigen’; ‘androgen receptor’; ‘advanced prostate cancer’; ‘castration‐resistant prostate cancer’; ‘biomarkers’. Bibliographies of relevant articles were searched for additional references. Relevant medical society and regulatory agency web sites from the USA and E urope were accessed for issued guidance on PSA use. PSA doubling time ( PSADT ) is a useful metric for determining which patients should be considered for androgen‐deprivation therapy ( ADT ) after failing local treatment or for second‐line therapies after failing ADT . However, it is not a validated surrogate for survival and no therapy has received regulatory approval based upon PSADT characteristics. PSA nadir and time‐to‐nadir have been identified as possible prognostic markers for patients receiving ADT . There is no universally accepted definition for PSA progression, nor is PSA progression a regulatory‐approved surrogate for clinical progression in drug approval trials. PSA responses to second‐line therapies can vary and are not considered by regulatory agencies as valid surrogates for clinical endpoints, so they must be assessed in the context of each individual therapy and trial design. PSA expression in CRPC is often a reflection of persistent androgen receptor activity. While we can provide guidance for use of PSA monitoring in managing patients with advanced prostate cancer based on the data at hand, there is an urgent need for prospective analyses of refined PSA metrics in conjunction with newer prostate cancer biomarkers in clinical trials to provide stronger evidence for their roles as surrogate endpoints.
- 1 November 2012
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 188 (5) , 1726-1731
Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases
The detection of prostate cancer relies primarily on abnormal digital rectal examination or increased serum prostate specific antigen concentration. However, low positive predictive values result in many men with increased prostate specific antigen and/or suspicious digital rectal examination having a negative biopsy. We investigated the value of the PCA3 (prostate cancer gene 3) urine test in predicting the likelihood of diagnosis of cancer before biopsy. We performed a prospective, community based clinical trial to evaluate PCA3 score before any biopsy. This trial was conducted at 50 urology practices in the United States. Samples were obtained from 1,962 men with increased serum prostate specific antigen (greater than 2.5 ng/ml) and/or abnormal digital rectal examination before transrectal prostate needle biopsy. Study samples (urinary PCA3 and biopsies) were processed and analyzed by a central laboratory. Sensitivity-specificity analyses were conducted. A total of 1,913 urine samples (97.5%) were adequate for PCA3 testing. Of 802 cases diagnosed with prostate cancer 222 had high grade prostatic intraepithelial neoplasia or atypical small acinar proliferation and were suspicious for cancer, whereas 889 cases were benign. The traditional PCA3 cutoff of 35 reduced the number of false-positives from 1,089 to 249, a 77.1% reduction. However, false-negatives (missed cancers) increased significantly from 17 to 413, an increase of more than 2,300%. Lowering the PCA3 cutoff to 10 reduced the number of false-positives 35.4% and false-negatives only increased 5.6%. Urinary PCA3 testing in conjunction with prostate specific antigen has the potential to significantly decrease the number of unnecessary prostate biopsies.
- 1 November 2012
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 188 (5) , 1726-1731
Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases
The detection of prostate cancer relies primarily on abnormal digital rectal examination or increased serum prostate specific antigen concentration. However, low positive predictive values result in many men with increased prostate specific antigen and/or suspicious digital rectal examination having a negative biopsy. We investigated the value of the PCA3 (prostate cancer gene 3) urine test in predicting the likelihood of diagnosis of cancer before biopsy. We performed a prospective, community based clinical trial to evaluate PCA3 score before any biopsy. This trial was conducted at 50 urology practices in the United States. Samples were obtained from 1,962 men with increased serum prostate specific antigen (greater than 2.5 ng/ml) and/or abnormal digital rectal examination before transrectal prostate needle biopsy. Study samples (urinary PCA3 and biopsies) were processed and analyzed by a central laboratory. Sensitivity-specificity analyses were conducted. A total of 1,913 urine samples (97.5%) were adequate for PCA3 testing. Of 802 cases diagnosed with prostate cancer 222 had high grade prostatic intraepithelial neoplasia or atypical small acinar proliferation and were suspicious for cancer, whereas 889 cases were benign. The traditional PCA3 cutoff of 35 reduced the number of false-positives from 1,089 to 249, a 77.1% reduction. However, false-negatives (missed cancers) increased significantly from 17 to 413, an increase of more than 2,300%. Lowering the PCA3 cutoff to 10 reduced the number of false-positives 35.4% and false-negatives only increased 5.6%. Urinary PCA3 testing in conjunction with prostate specific antigen has the potential to significantly decrease the number of unnecessary prostate biopsies.
- 1 January 2012
- Published by Touch Medical Media, Ltd. in Oncology & Hematology Review
- Vol. 08 (02)
Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective
Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have shown significant improvements in survival—over mitoxantrone (for cabazitaxel) and over placebo (for sipuleucel-T and abiraterone acetate)—and were well tolerated. There are also two treatments in late-stage development, MDV3100 (an oral AR antagonist) and radium-223 (an isotope that creates breaks in double-stranded DNA). These have also shown improvements in survival in Phase III trials; their regulatory approval is expected soon. The modes of actions of the existing and new drugs in CRPC are varied, but some are complementary and investigations of different combinations of these medications are much needed; they may enhance efficacy, further extend survival, and improve outcomes in this formerly untreatable disease.
- 1 January 2012
- Published by Touch Medical Media, Ltd. in Oncology & Hematology Review
- Vol. 08 (02)
Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective
Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have shown significant improvements in survival—over mitoxantrone (for cabazitaxel) and over placebo (for sipuleucel-T and abiraterone acetate)—and were well tolerated. There are also two treatments in late-stage development, MDV3100 (an oral AR antagonist) and radium-223 (an isotope that creates breaks in double-stranded DNA). These have also shown improvements in survival in Phase III trials; their regulatory approval is expected soon. The modes of actions of the existing and new drugs in CRPC are varied, but some are complementary and investigations of different combinations of these medications are much needed; they may enhance efficacy, further extend survival, and improve outcomes in this formerly untreatable disease.
- 25 November 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 30 (2) , 137-142
Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts
This article aims to review the merits of the use of prostate-specific antigen (PSA) as a screening tool in the detection of prostate cancer and the evidence presented by the US and European population-based, randomized controlled trials evaluating screening. Many studies have attempted to ascertain whether PSA screening is beneficial with respect to cancer-specific mortality. This report aims to clarify the issues specific to the PSA test, prostate cancer, sources of bias, and the future of screening. We performed an Ovid-Medline literature search for articles pertaining to the introduction of the PSA test, its use for screening for prostate cancer, confounders and biases specific to PSA and prostate cancer’s natural history, and reports specific to the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial (PLCO), and the European Randomized Study of Screening for Prostate Cancer (ERSPC). We reviewed these articles and present relevant data. PSA emerged as one of the most-used serum tests to screen for cancer, particularly in the US, but in Europe as well. The PLCO trial showed no benefit to screening, and the ERSPC showed a 20% relative risk reduction of cancer-specific mortality. This translated to an absolute reduction of PCa-related deaths of 0.71 per 1,000. Each trial has criticisms that may or may not have affected power and outcome, although the rate ratios comparing screening to not screening are similar. Definitive evidence for or against screening is still lacking, as interim analyses from the ERSPC and PLCO await further follow-up in the years to come.
- 25 November 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 30 (2) , 137-142
Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts
This article aims to review the merits of the use of prostate-specific antigen (PSA) as a screening tool in the detection of prostate cancer and the evidence presented by the US and European population-based, randomized controlled trials evaluating screening. Many studies have attempted to ascertain whether PSA screening is beneficial with respect to cancer-specific mortality. This report aims to clarify the issues specific to the PSA test, prostate cancer, sources of bias, and the future of screening. We performed an Ovid-Medline literature search for articles pertaining to the introduction of the PSA test, its use for screening for prostate cancer, confounders and biases specific to PSA and prostate cancer’s natural history, and reports specific to the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial (PLCO), and the European Randomized Study of Screening for Prostate Cancer (ERSPC). We reviewed these articles and present relevant data. PSA emerged as one of the most-used serum tests to screen for cancer, particularly in the US, but in Europe as well. The PLCO trial showed no benefit to screening, and the ERSPC showed a 20% relative risk reduction of cancer-specific mortality. This translated to an absolute reduction of PCa-related deaths of 0.71 per 1,000. Each trial has criticisms that may or may not have affected power and outcome, although the rate ratios comparing screening to not screening are similar. Definitive evidence for or against screening is still lacking, as interim analyses from the ERSPC and PLCO await further follow-up in the years to come.
- 28 June 2011
- Published by Wiley in BJU International
- Vol. 108 (11) , 1743-1749
Prostate‐specific antigen 1.5–4.0 ng/mL: a diagnostic challenge and danger zone
Study Type – Prognosis (inception cohort) Level of Evidence 1b What’s known on the subject? and What does the study add? Large population screening trials like the ERSPC, PCPT and PLCO have noted that men with seemingly low PSA (even as low as 0.5 ng/dL) still can have prostate cancer. Despite these findings, PSA is still predominantly used as a current indicator for possible presence of prostate cancer rather than also serving as a prognostic marker. This study examines a larger number of men in a diverse US population to determine the prognostic value of a man’s baseline or first PSA. OBJECTIVES: • To assess the value of a PSA threshold of 1.5 ng/mL as a predictor of increased prostate cancer risk over a four‐year period based on a man’s first PSA test, including racial differences. • To review the risk of progression of benign prostatic hyperplasia (BPH) based on a similar PSA threshold. PATIENTS AND METHODS: • A retrospective review involving 21 502 men from a large Midwestern health system was performed. • Men at least 40 years old with baseline PSA values between 0 and 4.0 ng/mL and at least four years of follow‐up after initial PSA test were included. • Optimal PSA threshold and predictive value of PSA for development of prostate cancer were calculated. RESULTS: • Prostate cancer rates were 15‐fold higher in patients with PSA ≥1.5 ng/mL vs patients with PSA <1.5 ng/mL (7.85% vs 0.51%). • African American patients with baseline PSA <1.5 ng/mL faced prostate cancer rates similar to the whole study population (0.54% vs 0.51%, respectively), while African American patients with PSA 1.5–4.0 ng/mL faced a 19‐fold increase in prostate cancer. CONCLUSION: • Both Caucasian and African American men with baseline PSA values between 1.5 and 4.0 ng/mL are at increased risk for future prostate cancer compared with those who have an initial PSA value below the 1.5 ng/mL threshold. • Based on a growing body of literature and this analysis, it is recommended that a first PSA test threshold of 1.5 ng/mL and above, or somewhere between 1.5 and 4.0 ng/mL, represent the Early‐Warning PSA Zone (EWP Zone). • This should serve to inform patients and clinicians alike to future clinical activities with respect to prostate cancer and BPH.
- 28 June 2011
- Published by Wiley in BJU International
- Vol. 108 (11) , 1743-1749
Prostate‐specific antigen 1.5–4.0 ng/mL: a diagnostic challenge and danger zone
Study Type – Prognosis (inception cohort) Level of Evidence 1b What’s known on the subject? and What does the study add? Large population screening trials like the ERSPC, PCPT and PLCO have noted that men with seemingly low PSA (even as low as 0.5 ng/dL) still can have prostate cancer. Despite these findings, PSA is still predominantly used as a current indicator for possible presence of prostate cancer rather than also serving as a prognostic marker. This study examines a larger number of men in a diverse US population to determine the prognostic value of a man’s baseline or first PSA. OBJECTIVES: • To assess the value of a PSA threshold of 1.5 ng/mL as a predictor of increased prostate cancer risk over a four‐year period based on a man’s first PSA test, including racial differences. • To review the risk of progression of benign prostatic hyperplasia (BPH) based on a similar PSA threshold. PATIENTS AND METHODS: • A retrospective review involving 21 502 men from a large Midwestern health system was performed. • Men at least 40 years old with baseline PSA values between 0 and 4.0 ng/mL and at least four years of follow‐up after initial PSA test were included. • Optimal PSA threshold and predictive value of PSA for development of prostate cancer were calculated. RESULTS: • Prostate cancer rates were 15‐fold higher in patients with PSA ≥1.5 ng/mL vs patients with PSA <1.5 ng/mL (7.85% vs 0.51%). • African American patients with baseline PSA <1.5 ng/mL faced prostate cancer rates similar to the whole study population (0.54% vs 0.51%, respectively), while African American patients with PSA 1.5–4.0 ng/mL faced a 19‐fold increase in prostate cancer. CONCLUSION: • Both Caucasian and African American men with baseline PSA values between 1.5 and 4.0 ng/mL are at increased risk for future prostate cancer compared with those who have an initial PSA value below the 1.5 ng/mL threshold. • Based on a growing body of literature and this analysis, it is recommended that a first PSA test threshold of 1.5 ng/mL and above, or somewhere between 1.5 and 4.0 ng/mL, represent the Early‐Warning PSA Zone (EWP Zone). • This should serve to inform patients and clinicians alike to future clinical activities with respect to prostate cancer and BPH.
- Open Access
- 23 May 2011
- Published by Medknow in Asian Journal of Andrology
- Vol. 13 (5) , 655-656
Prostate-specific antigen (PSA) screening: has the pendulum swung too far?
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- 23 May 2011
- Published by Medknow in Asian Journal of Andrology
- Vol. 13 (5) , 655-656
Open AccessProstate-specific antigen (PSA) screening: has the pendulum swung too far?
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.